Switzerland-based Siegfried has purchased a 95% stake in DiNAMIQS, a biotechnology firm that focuses on the development and production of viral vectors for cell and gene therapies.
Siegfried will leverage DiNAMIQS’ capabilities to commercial scale by constructing a facility that complies with good manufacturing practice standards.
The facility will be situated with DiNAMIQS’ existing operations at Bio-Technopark in Zurich-Schlieren, Switzerland, and is anticipated to become operational in 2025.
DiNAMIQS’ parent company, DiNAQOR, will own the remaining 5% stake in the firm.
The deal includes an option for Siegfried to purchase this remaining 5% five years after the acquisition.
The move represents Siegfried’s strategy to expand its presence in biologics, and provides important growth opportunities in the mid to long term.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataDiNAMIQS will initially continue to run under its own name and as a mostly independent venture within Siegfried.
DiNAMIQS and its clients will take advantage of the integration of its drug substances production activities into Siegfried’s capabilities, as well as the capacities for the aseptic filling and completion of complex biological entities at its facilities in Hameln, Germany, and Irvine in the US.
Siegfried CEO Dr Wolfgang Wienand stated: “With this acquisition, we are entering the rapidly growing space of cell and gene therapies where viral vector-based technologies support the majority of clinical candidates in a rich development pipeline.
“In our view, this approach of an initial small-scale acquisition of a highly capable technology platform followed by flexible bolt-on investments into capabilities and capacities in line with actual market needs, provides significant value upside at reasonable entry costs.
“This is perfectly in line with our EVOLVE strategy and our track record of disciplined execution of value-adding mergers and acquisitions – and a further step towards our vision of creating a leading contract development and managing organisation in our space.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
